sightsciences-logo
  • About
  • OMNI
  • Glaucoma
  • Newsroom
  • Contact Us
  • Investors
  • Home
  • Newsroom
  • Events

Newsroom

News
43
Events
4
OMNI
15
TearCare
2
All
52
Top Results
News
Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
News
Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023
News
Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer
News
Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results
June 03, 2021
Event: European AECOS

Event Details June 3-6 Florence, Italy Contact Sight Sciences today to schedule a meeting.

read more +
June 17, 2021
Event: Congress of German Ophthalmic Surgeons (DOC)

Event Details June 17-19 Nuremberg, Germany Contact Sight Sciences today to schedule a meeting.

read more +
June 30, 2021
Event: World Glaucoma Congress (WGC)

Event Details June 30- July 3 VIRTUAL Contact Sight Sciences today to schedule a meeting.

read more +
August 27, 2021
Event: European Society of Cataract and Refractive Surgeons (ESCRS)

Event Details August 27-30 Amsterdam, Netherlands Contact Sight Sciences today to schedule a meeting.

read more +
    Thank You

    We appreciate your interest in Sight Sciences and our products. A member of our team will review your inquiry and follow up with you during business hours.

    Disclamer

    In providing these materials requested by you, the physician, Sight Sciences does not intend to support or endorse any presentations, communications, or other messages you may impart through the use of these materials.

    If and when you use the materials in a presentation, communication, or other message, please include a disclaimer that the statements and opinions in the presentation/communication/message are entirely your own and are not supported or endorsed by Sight Sciences.

    Accept decline
    Indications and Safety for OMNI™ Surgical System

    Indications for use

    The OMNI™ Glaucoma Treatment System is indicated for the catheterization and transluminal viscodilation of Schlemm’s canal and the cutting of trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma.

    Contraindications

    1. Do not use the OMNI in any situations where the angle is compromised or has been damaged (e.g., from trauma or surgery), since it may not be possible to visualize the angle or to properly pass the microcatheter.
    2. Do not use the OMNI in patients with angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlet canals with plateau iris.

    Warnings

    1. Do not use in cases where there is insufficient visibility to properly see the angle. The following conditions may prohibit sufficient visualization of the angle required for safe and successful cannula placement: corneal edema, corneal haze, corneal opacity, or any other conditions that may inhibit gonioscopic view of the angle and intended cannula entry location.
    2. Perform gonioscopy prior to taking a patient to surgery to exclude congenital anomalies of the angle, anterior segment dysgeneses, peripheral anterior synechiae (PAS), rubeosis, and any other angle abnormalities that could lead to improper placement of the cannula and microcatheter and pose a hazard.
    3. Maintain direct microscopic or gonioscopic visualization of the cannula tip and microcatheter tip at all times during the procedure to facilitate advancement and to avoid inadvertently damaging intraocular structures, kinking the microcatheter or unintended tearing of trabecular meshwork.

    Potential adverse events

    Adverse events that may be reasonably associated with the use of the OMNI™ System in the eye include but are not limited to the following: anterior chamber shallowing, severe, prolonged, or persistent intraocular inflammation including toxic anterior segment syndrome (TASS), endophthalmitis or other ocular infection, aqueous misdirection, Descemet’s membrane tear or detachment, intracorneal hematoma, choroidal effusion, suprachoroidal hemorrhage, corneal decompensation, corneal injury, corneal edema or opacification, unintended trabeculotomy, cyclodialysis cleft, hyphema, hypopyon, hypotony, hypotony maculopathy, IOL dislocation, cataract formation, iris injury, tear, or iridodialysis, loss of vitreous, perforation of sclera, posterior capsular bag rupture, proliferative vitreoretinopathy, pupillary block, pupillary membrane formation, retinal detachment, retinal dialysis, retinal flap tears, secondary surgical intervention, including but not limited to glaucoma surgery, and vitreous hemorrhage.

    4040 Campbell Ave, Suite 100
    Menlo Park CA 94025

    T: 877-266-1144E: Info@sightsciences.com
    flag
    International
    • flag
      United States
    • flag
      International
    Indications and Safety for OMNI™ Surgical System
    READ MORE

    OMNI® Surgical System and TearCare® are commercially available in the United States.
    OMNI® and TearCare® are registered trademarks of Sight Sciences. SmartLids™, SmartHub™, and Clearance Assistant™ are trademarks of Sight Sciences and for use only by Sight Sciences.
    OMNI Surgical System is CE Marked in the European Union

    © 2023 Sight Sciences, Inc. 10/21 SS-1181-OUS.v7
    Privacy Policy
    Cookie Policy
    Patents
    Compliance
    Investors
    graphic lines 2